Reuters logo
BRIEF-Voyager Therapeutics announces positive interim results from phase 1B trial of VY-AADC01
December 7, 2016 / 9:36 PM / 9 months ago

BRIEF-Voyager Therapeutics announces positive interim results from phase 1B trial of VY-AADC01

Dec 7 (Reuters) - Voyager Therapeutics Inc

* Says VY-AADC01 dose-dependently improved measures of motor function and enhanced response to levodopa at 6 and 12 months

* Says administration of VY-AADC01 was well-tolerated

* Says program on track to report cohort 3 data mid-2017 and to begin placebo-controlled trial Q4, 2017

* Voyager therapeutics announces positive interim results from phase 1B trial of VY-AADC01 for advanced parkinson’s disease Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below